When: Close above $369 with volume

Then: Complete 35% final tranche on breakout confirmation

HOLD/WATCH - Do not buy; wait for AVGO to reclaim the 200-day moving average at $369 on a full candle close with volume confirmation, RSI above 45, and MACD histogram crossing positive before considering entry.

• Morgan Stanley price target upgrade is "research theater" not capital commitment; 60 million share down day with stock breaking below 200-day moving average support contradicts the bullish signal
• Forward EPS of $19.33 vs trailing EPS of $7.86 represents 146% expected EPS jump; PEG of 0.42 is only attractive due to heroic forward assumptions that could collapse if guidance slips by even one quarter
• AVGO has 1.46 beta, meaning market treats it as high-beta growth regardless of the 18.5x forward P/E multiple; 27% drawdown occurred because market repriced execution risk
• Bottleneck-as-moat argument is incomplete: if supply constrains deployment, upside is capped near-term and any substrate disruption compresses the very revenue guidance the bull case depends on
• Scale-in structure exposes capital to compounding losses in "wrong thesis" scenario: Tranche 1 stopped at $332 (7.2% loss) means Tranche 2 at $340-345 is closer to falling knife than original entry
• Risks are correlated not independent: if AI capex digestion hits, multiple compression, execution failure, and macro tightening occur simultaneously as symptoms of the same shift
• Customer concentration risk: Apple, Google, Meta represent massive revenue chunk; Nvidia's $12.9 billion Hugging Face acquisition signals intensifying custom silicon competition

→ vs aggressive: Morgan Stanley upgrade argument is flawed: one price target update is not capital commitment, and it occurred on the same day as a 60 million share down day breaking below 200-day moving average with RSI at 38 and negative MACD - the tape contradicts institutional "smart money" narrative

→ vs aggressive: Waiting for $369 confirmation is not "buying high" - it pays a 3% premium for certainty that the trend has shifted, serving as insurance against catching a falling knife in a 1.46 beta name already down 27%

→ vs aggressive: PEG of 0.42 is a function of heroic forward assumptions, not intrinsic value; if EPS guidance slips, forward P/E could expand from 18.5x to 35-40x on actual earnings, making the stock significantly more expensive

→ vs aggressive: Low forward P/E of 18.5x does not protect against beta-driven drawdowns; 1.46 beta means AVGO moves with high-growth cohort during risk-off periods regardless of valuation metrics

→ vs aggressive: Scale-in tranches expose capital to compounding losses: Tranche 1 wrong means Tranche 2 is adding risk to a broken chart, not averaging down safely; Tranche 3 requires buying strength after recovery, missing the efficient entry

→ vs aggressive: Probability math treating risks as independent events is flawed; correlated risks (multiple compression, execution failure, macro deterioration) reinforce each other, which is why the 27% drawdown occurred

→ vs aggressive: Bear case risks missing from bullish thesis: Nvidia's $12.9 billion Hugging Face acquisition signals intensifying competition in custom silicon market AVGO dominates; customer concentration on Apple, Google, Meta creates vulnerability to silicon roadmap shifts

HOLD: Reduce Tranche 1 to 25-30% of intended size at $358; restructure or eliminate Tranche 2 at $340-345 (replace with MACD histogram cross or higher-low formation trigger); keep Tranche 3 at confirmed break above $369 with volume; tighten stop to $345 instead of $332; consider protective puts or collar hedging; ensure portfolio diversification beyond high-beta AI names.

• PEG of 0.42 is derived from forward EPS assumption of $19.33; if actual EPS comes in at $15, multiple expands to ~24x and valuation is not compelling
• Bottleneck-as-moat argument is one-sided: supply constraints cap both deployment and near-term revenue ramp regardless of demand strength
• Correlated risks in high-beta AI name with customer concentration reinforce each other (multiple compression + execution delay + macro tightening simultaneously)
• Scale-in structure at Tranche 2 ($340-345) creates psychological pressure to average down into a potentially failing thesis
• Waiting for $369 confirmation with RSI above 45 and MACD positive may result in 10-12% higher entry, compressing asymmetric payoff
• Institutional research base (Morgan Stanley $505 PT, Morningstar 2028 outlook beat, multiple analyst upgrades) represents counter-signal to retail capitulation and WSB sentiment
• Stop at $332 aligns with lower Bollinger band; tightening to $345 respects recent $355-358 consolidation and limits per-trade loss to ~4% vs 7%
• High conviction and high uncertainty can coexist; small premium for downside protection is rational when entering broken technical structure on beta 1.46 name
• AVGO is fundamentally elite business in technically damaged position with macro headwind and execution-dependent valuation case

→ vs aggressive: Treats PEG of 0.42 as fact about the world rather than derived metric dependent on near-perfect AI revenue execution; if forward EPS comes in at $15 instead of $19.33, PEG jumps to 0.55 and stock is richly-priced cyclical with execution risk

→ vs aggressive: Bottleneck-as-moat argument ignores that same bottlenecks cap deployment; Tan explicitly stated demand could be 'significantly higher' but land, power, chips, and substrates are gating revenue recognition, creating near-term upside cap while downside remains

→ vs aggressive: Probability math on correlated risks was sloppy; risks in high-beta AI name with customer concentration do not behave like independent dice rolls but reinforce each other as one risk with three faces

→ vs conservative: Waiting for $369 confirmation with RSI above 45 and MACD positive is too rigid for name with institutional credibility, elite margins, and FCF generation; technical confirmation often lags fundamental inflection by weeks or months, potentially costing 10-12% higher entry

→ vs conservative: Framing Morgan Stanley upgrade as 'research theater' is dismissive and ignores broader pattern: macro report flagged Morningstar 2028 outlook beat, multiple analyst upgrades, and $505 target citing management roadmap; not one analyst but cluster of institutions maintaining conviction

→ vs conservative: Scale-in structure assumes Tranche 1 levels are reachable AND supportive; if Tranche 1 stops out at $332, Tranche 2 was never triggered, and if stock chops sideways around $350, Tranche 2 creates psychological pressure to average down into working thesis that may not be working